CVS Health stock has delivered a strong 83.1% return over the past year, yet the broader valuation checks and current market multiples suggest the shares are not an obvious bargain at today’s level.

• The 83.1% one year gain signals a powerful rerating that raises the bar for what future cash flows and earnings need to justify.
• Recent legal and regulatory developments around drug pricing and pharmacy practices can support investor confidence if they reduce uncertainty over time, but they also highlight ongoing headline and compliance risk that may influence what investors are willing to pay for CVS Health.
• With CVS Health scoring only 2 out of 6 on valuation checks, the stock currently appears more expensive than a clear value opportunity on these measures.

The key question for investors is whether CVS Health’s recent share price strength leaves enough potential upside to compensate for the risks that are still in plain view.

Has CVS Health Run Too Far on Earnings?

The P/E ratio is a useful comparison tool for CVS Health because earnings remain a key focus for how the market prices large, mature healthcare companies.

CVS Health currently trades on a P/E of 46.9x, which is well above the Healthcare industry average of 25.9x and the peer average of 20.4x. That premium is also high relative to a fair P/E of 40.6x, which reflects what might be expected given the company’s mix of businesses, risk profile and sector exposure. In other words, the market is asking investors to pay a higher price per dollar of earnings than broad industry benchmarks and this tailored fair level suggest.

Despite the recent FTC settlement aiming to reduce uncertainty around CVS Health’s drug pricing and pharmacy benefit practices, the stock is still priced on a multiple that already builds in a lot of optimism compared with peers.

On this P/E yardstick, CVS Health appears expensive, with the market paying a sizeable premium to both industry norms and its own fair multiple.

The CVS Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for CVS Health pick up from this valuation puzzle, spelling out which assumptions about CVS Health's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price, and they sit on Simply Wall St's Community page. Rather than leaning on a single multiple or model, each Narrative lays out the key moving parts behind its view of fair value so you can compare those expectations with the actual results as they are reported over time.

Community views on CVS Health sit far apart, with one camp seeing a vertically integrated healthcare platform taking shape and another focused on whether the reset has gone far enough yet.

Bull case: roughly fairly valued

"Integration of recent and ongoing acquisitions (such as Aetna, Oak Street, and Signify Health) and vertical alignment between insurance, pharmacy, and care delivery provide substantial cross-selling and synergy opportunities, supporting long-term operating margin and earnings growth as margin recovery initiatives gain traction…"

Bear case: roughly fairly valued

"The result has been increasing uncertainty, thanks in part to leadership changes and rising medical costs, with investors questioning whether CVS can indeed make the shift from retail to a healthcare model…"

Do you think there's more to the story for CVS Health? Head over to our Community to see what others are saying!

The Bottom Line

For now, CVS Health screens as overvalued on market multiples, with the current P/E leaving little room for disappointment relative to peers and its own tailored fair level. The low overall valuation score suggests that, across several checks, the stock does not stand out as a clear value opportunity despite recent progress on regulatory uncertainty.

What matters most from here is whether CVS Health can deliver the earnings and margin profile that supporters expect from its vertically integrated model, without fresh legal or execution setbacks. That tension between potential benefits from integration and ongoing risk is the core question investors need to weigh at today’s price.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.